The Ministry of Health and Quality of Life has listed buprenorphine as a Schedule II medicine under the new Dangerous Drugs Act 2000. This is because abuse of the drug by intravenous as opposed to oral use has been reported to cause a number of deaths. (Reference: Letter to WHO from the Ministry of Health and Quality of Life, Port Louis, Mauritius, 27 December 2000.)